Revance Therapeutics, Inc.
RVNC · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $541 | $267 | $435 | $792 |
| - Cash | $59 | $82 | $133 | $138 |
| + Debt | $483 | $492 | $476 | $478 |
| Enterprise Value | $966 | $677 | $777 | $1,133 |
| Revenue | $60 | $65 | $52 | $70 |
| % Growth | -8.4% | 25.9% | -25.6% | – |
| Gross Profit | $42 | $46 | $35 | $51 |
| % Margin | 70.6% | 70.8% | 67.5% | 72.9% |
| EBITDA | -$29 | -$30 | -$42 | -$49 |
| % Margin | -47.8% | -46.4% | -81.4% | -70% |
| Net Income | -$35 | -$37 | -$53 | -$56 |
| % Margin | -58.6% | -57.3% | -102.3% | -79.8% |
| EPS Diluted | -0.34 | -0.36 | -0.58 | -0.62 |
| % Growth | 5.6% | 37.9% | 6.5% | – |
| Operating Cash Flow | -$41 | -$41 | -$66 | -$43 |
| Capital Expenditures | -$0 | -$0 | -$2 | -$2 |
| Free Cash Flow | -$41 | -$42 | -$68 | -$45 |